

WG-I-2019 Final minutes 29.03.2019

# Minutes of Efficacy WG-I-2019 22 January 2019

Meeting of the Efficacy Working Group of the Biocidal Products Committee

## **Efficacy Working Group**

### 1. Welcome and apologies

The Chair welcomed all participants to the 26<sup>th</sup> Efficacy WG virtual meeting. There were three core and one alternate members and 13 flexible members who participated in the meeting. In addition one stakeholder representative and the applicant were present.

Participants were informed that the meeting would be recorded solely for the purposes of writing the minutes and that this recording would be destroyed after the agreement of the minutes. The list of attendees is given in Annex 1.

#### 2. Administrative issues

SECR gave a brief information on the administrative issues.

#### 3. Agreement of the agenda

The Chair introduced the agenda items. The EFF WG members agreed on the proposed agenda.

DE proposed to add under AOB a point related to working procedure in order to get an EFF WG agreement on discussed/consulted items.

# 4. Declarations of potential conflicts of interest in relation to the agenda

The Chair invited all members to declare any potential conflict of interest to the agenda items. None were declared.

#### 5. Minutes

In relation to the EFF WG-VI-2018 meeting in November no comments were received, so the draft minutes were considered as agreed.

With reference to the EFF WG-VII-2018 meeting in December comments from DE and a question from AT were received related to the general minutes. The EFF WG agreed with the proposals made by DE. With reference to AT question a clarifying sentence was added to the final general minutes. The EFF WG agreed on the general minutes.

With reference to the respective draft minutes related to the EFF WG discussion on UA-APPs the EFF WG members were informed that conclusions reached during ad hoc-follow up procedure were included in the draft minutes. The EFF WG agreed on the respective minutes.

#### 6. AOB

#### 6.1 Request to ECHA for an opinion pursuant to Articles 36(2) and 38 of the BPR

COM has addressed to ECHA a request for a BPC opinion related to unresolved objection during the notification of the biocidal product acting as a repellent for birds in order to decide on the authorisation of the product. DE critically questioned the setup of the negative controls in the study. Further doubts raised at the EFF WG were related to the dual mode of action of this product. Based on submitted efficacy data it was not possible to determine if efficacy is due to the presence of active substances, or only due to UV light emission to which birds are sensitive. Further, DE pointed to published studies, that similar products may lead to unacceptable suffering of the target organisms.

The bibliography provided by the eCA was considered not supportive for this specific case as the active substances and bird species tested were different.

Nevertheless, even though the submitted efficacy studies were not conducted ideally, it was pointed out that efficacy of the product in the form in which it is supplied to the user is demonstrated.

Considering the applicable guidance at the time of submission, the expert judgement applied by the eCA, and the field studies provided, the EFF WG agreed with the eCA that efficacy of the product is sufficiently demonstrated for the claimed use.

#### 6.2 Other information & lessons learned

The Chair informed that the next EFF meeting will take place 27-29 of March 2019. It will be a physical meeting in Helsinki, with four UA applications, Appendix 4 of PT1-5, PT11/12 and PT19 efficacy guidance for discussion. New ECHA structure was presented as well. With reference to e-consultations the EFF WG members were informed that e-consultations related to NA issues have to be launched by initiating MS (iMS) via e-mail. Nevertheless the iMSs are invited to send summaries to ECHA to be uploaded into S-CIRCABC. Newsgroups will be created by ECHA only for e-consultations related to UA, AS approvals or ongoing developments/revisions of efficacy guidance.

The Chair also informed about issues identified during the discussions on UA applications, which need to be solved as soon as possible:

- 1. Number of concentrations to be tested in efficacy studies
- 2. Definition + testing of different surface application methods
- 3. Contact time (CT) for wipes, especially for highly volatile substances
- 4. Surface disinfection test for other test organisms than bacteria and yeast (fungi, mycobacteria, viruses)

The EFF WG members were invited to volunteer for the items mentioned above and prepare relevant documents for discussion. This information should be sent to ECHA by mid-February 2019. AT volunteered to take care of item 3: Contact time (CT) for wipes, especially for highly volatile substances.

#### 6.3 Additional item for discussion proposed by DE - written procedure for WG agreement

DE pointed out that some of the EFF WG e-consultations are not conclusive, and it is difficult for the initiating MS to take any decision. Therefore, DE proposed to introduce a new tool, i.e. written procedure to get WG agreement and facilitate future discussions. As an example the procedure developed by the Endocrine Disruptors WG was given. DE will be contacted by ECHA to discuss the way forward.

# **List of Attendees**

# **Efficacy Working Group**

Core members
ESCH Daniel (DE)
ATTIG Isabelle (FR)
POULIS Joan (NL)
Alternate members
SMITH Ryan (UK) - Rapporteur
Flexible members
ZUTZ Christoph (AT)
LEPAGE Anne (BE)
PEELMAN Natania (BE)
BUEHLER Dominique (CH)
ROSSIER Nadine (CH)
GURBA Alexandre (CH)
PEČÍNKOVÁ Martina (CZ)
CLEYTON JØRGENSEN Charlotte (DK)
FISCHER Juliane (DE)
RYDMAN Elina (FI)
ILMARINEN Kaja (EE)
WIGGERS Hanneke (NL)
HUSZAL Sylwester (PL)